{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T12:34:26Z","timestamp":1718714066095},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1007\/s11906-001-0095-6","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T20:57:46Z","timestamp":1180126666000},"page":"322-330","source":"Crossref","is-referenced-by-count":21,"title":["The therapeutic potential of endothelin receptor antagonists in cardiovascular disease"],"prefix":"10.1007","volume":"3","author":[{"given":"Matthias","family":"Barton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Kiowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"95_CR1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/288373a0","volume":"299","author":"RF Furchgott","year":"1980","unstructured":"Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 299:373\u2013376.","journal-title":"Nature"},{"key":"95_CR2","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","volume":"84","author":"LJ Ignarro","year":"1987","unstructured":"Ignarro LJ, Buga GM, Wood KS, et al.: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84:9265\u20139269.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"95_CR3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/01.RES.51.4.439","volume":"51","author":"JG Mey De","year":"1982","unstructured":"De Mey JG, Vanhoutte PM: Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 1982, 51:439\u2013447.","journal-title":"Circ Res"},{"key":"95_CR4","doi-asserted-by":"crossref","first-page":"C550","DOI":"10.1152\/ajpcell.1985.248.5.C550","volume":"248","author":"KA Hickey","year":"1985","unstructured":"Hickey KA, Rubanyi GM, Paul RJ, Highsmith RF: Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985, 248:C550-C556.","journal-title":"Am J Physiol"},{"key":"95_CR5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/jcp.1041320210","volume":"132","author":"RF O\u2019Brien","year":"1987","unstructured":"O\u2019Brien RF, Robbins RJ, McMurtry IF: Endothelial cells in culture produce a vasoconstrictor substance. J Cell Physiol 1987, 132:263\u2013270.","journal-title":"J Cell Physiol"},{"key":"95_CR6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","volume":"332","author":"M Yanagisawa","year":"1988","unstructured":"Yanagisawa M, Kurihara H, Kimura S, et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411\u2013415.","journal-title":"Nature"},{"key":"95_CR7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.physiol.61.1.391","volume":"61","author":"T Miyauchi","year":"1999","unstructured":"Miyauchi T, Masaki T: Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999, 61:391\u2013415. Excellent up-to-date review of the discovery and actions of endothelins and their receptors.","journal-title":"Annu Rev Physiol"},{"key":"95_CR8","doi-asserted-by":"crossref","first-page":"14613","DOI":"10.1016\/S0021-9258(18)63739-1","volume":"264","author":"K Saida","year":"1989","unstructured":"Saida K, Mitsui Y, Ishida N: A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression and biological activity. J Biol Chem 1989, 264:14613\u201314616.","journal-title":"J Biol Chem"},{"key":"95_CR9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1006\/bbrc.1998.8980","volume":"248","author":"F Kishi","year":"1998","unstructured":"Kishi F, Minami K, Okishima N, et al.: Novel 31-amino acidlength endothelins cause constriction of vascular smooth muscle. Biochem Biophys Res Commun 1998, 248:387\u2013390.","journal-title":"Biochem Biophys Res Commun"},{"key":"95_CR10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/01.RES.85.10.906","volume":"85","author":"C Fernandez-Patron","year":"1999","unstructured":"Fernandez-Patron C, Radomski MW, Davidge ST: Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999, 85:906\u2013911. First description of a novel endothelin isoform derived from matrix metalloproteinase-2.","journal-title":"Circ Res"},{"key":"95_CR11","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1016\/S0021-9258(17)36997-1","volume":"269","author":"GF Alberts","year":"1994","unstructured":"Alberts GF, Peifley KA, Johns A, et al.: Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem 1994, 269:10112\u201310118.","journal-title":"J Biol Chem"},{"key":"95_CR12","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1172\/JCI118092","volume":"96","author":"H Fujisaki","year":"1995","unstructured":"Fujisaki H, Ito H, Hirata Y, et al.: Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995, 96:1059\u20131065.","journal-title":"J Clin Invest"},{"key":"95_CR13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1006\/bbrc.1997.7394","volume":"238","author":"M Barton","year":"1997","unstructured":"Barton M, Shaw S, d\u2019Uscio LV, et al.: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA-receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238:861\u2013865.","journal-title":"Biochem Biophys Res Commun"},{"key":"95_CR14","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1074\/jbc.270.12.6997","volume":"270","author":"S Iwasaki","year":"1995","unstructured":"Iwasaki S, Homma T, Matsuda Y, Kon V: Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem 1995, 270:6997\u20137003.","journal-title":"J Biol Chem"},{"key":"95_CR15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00041552-199909000-00003","volume":"8","author":"M Barton","year":"1999","unstructured":"Barton M, Luscher TF: Endothelin antagonists for hypertension and renal disease. Curr Opin Nephrol Hypertens 1999, 8:549\u2013556.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"95_CR16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.102.19.2434","volume":"102","author":"TF Luscher","year":"2000","unstructured":"Luscher TF, Barton M: Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102:2434\u20132440.","journal-title":"Circulation"},{"key":"95_CR17","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0006-2952(92)90252-E","volume":"43","author":"DM Wypij","year":"1992","unstructured":"Wypij DM, Nichols JS, Novak PJ, et al.: Role of mast cell chymase in the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem Pharmacol 1992, 43:845\u2013853.","journal-title":"Biochem Pharmacol"},{"key":"95_CR18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1172\/JCI9997","volume":"107","author":"C Guo","year":"2001","unstructured":"Guo C, Ju H, Leung D, et al.: A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest 2001, 107:703\u2013715.","journal-title":"J Clin Invest"},{"key":"95_CR19","doi-asserted-by":"crossref","first-page":"32469","DOI":"10.1074\/jbc.274.45.32469","volume":"274","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Emoto N, Raharjo SB, et al.: Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. J Biol Chem 1999, 274:32469\u201332477.","journal-title":"J Biol Chem"},{"key":"95_CR20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1042\/bj3270023","volume":"327","author":"MV Hoang","year":"1998","unstructured":"Hoang MV, Turner AJ: Novel activity of endothelin-converting enzyme: hydrolysis of bradykinin. Biochem J 1998, 327:23\u201326. This paper describes actions of ECE-1, which go beyond cleavage of big ET-1, suggesting multiple functions for this enyzme in cardiovascular disease.","journal-title":"Biochem J"},{"key":"95_CR21","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1006\/bbrc.1994.1395","volume":"199","author":"T Fukuroda","year":"1994","unstructured":"Fukuroda T, Fujikawa T, Ozaki S, et al.: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994, 199:1461\u20131465.","journal-title":"Biochem Biophys Res Commun"},{"key":"95_CR22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/01.CIR.97.8.752","volume":"97","author":"MC Verhaar","year":"1998","unstructured":"Verhaar MC, Strachan FE, Newby DE, et al.: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998, 97:752\u2013756.","journal-title":"Circulation"},{"key":"95_CR23","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1161\/01.CIR.96.6.1976","volume":"96","author":"P Mulder","year":"1997","unstructured":"Mulder P, Richard V, Derumeaux G, et al.: Role of endogenous endothelin in chronic heart failure. Effect of long-term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. Circulation 1997, 96:1976\u20131782.","journal-title":"Circulation"},{"key":"95_CR24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","volume":"346","author":"W Kiowski","year":"1995","unstructured":"Kiowski W, S\u00fctsch G, Hunziker P, et al.: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995, 346:732\u2013736.","journal-title":"Lancet"},{"key":"95_CR25","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","volume":"98","author":"G S\u00fctsch","year":"1998","unstructured":"S\u00fctsch G, Kiowski W, Yan XW, et al.: Short-term oral endothelinreceptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998, 98:2262\u20132268. This study extends the previous work of the authors, demonstrating that the beneficial hemodynamic effects are maintained after several weeks of treatment with the dual antagonist bosentan.","journal-title":"Circulation"},{"key":"95_CR26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/368703a0","volume":"368","author":"Y Kurihara","year":"1994","unstructured":"Kurihara Y, Kurihara H, Suzuki H, et al.: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994, 368:703\u2013710.","journal-title":"Nature"},{"key":"95_CR27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/00912709922008380","volume":"39","author":"C Weber","year":"1999","unstructured":"Weber C, Banken L, Birnboeck H, Schulz R: Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol 1999, 39:847\u2013854.","journal-title":"J Clin Pharmacol"},{"key":"95_CR28","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1161\/01.CIR.96.4.1250","volume":"96","author":"JE Donckier","year":"1997","unstructured":"Donckier JE, Massart PE, Hodeige D, et al.: Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997, 96:1250\u20131256.","journal-title":"Circulation"},{"key":"95_CR29","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/ki.1993.263","volume":"44","author":"A Benigni","year":"1993","unstructured":"Benigni A, Zoja C, Corna D, et al.: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993, 44:440\u2013444.","journal-title":"Kidney Int"},{"key":"95_CR30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1517\/13543776.7.2.139","volume":"7","author":"A Begnini","year":"1997","unstructured":"Begnini A, Remuzzi G: The renoprotective potential of endothelin receptor antagonists. Exp Opin Ther Patents 1997, 7:139\u2013149.","journal-title":"Exp Opin Ther Patents"},{"key":"95_CR31","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1161\/01.HYP.34.4.876","volume":"34","author":"EL Schiffrin","year":"1999","unstructured":"Schiffrin EL: State-of-the-art lecture. Role of endothelin-1 in hypertension. Hypertension 1999, 34:876\u2013881.","journal-title":"Hypertension"},{"key":"95_CR32","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1172\/JCI119297","volume":"99","author":"B Hocher","year":"1997","unstructured":"Hocher B, Th\u00f6ne-Reinecke C, Rohmeiss P, et al.: Endothelin-1 transgenic mice develop glomerulosclerosis, intersitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997, 99:1380\u20131389.","journal-title":"J Clin Invest"},{"key":"95_CR33","first-page":"851","volume":"33","author":"FE Strachnan","year":"1999","unstructured":"Strachnan FE, Spratt JC, Wilkinson IB, et al.: Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999, 33:851\u2013855. This study demonstrated the importance of the ETB receptor in maintaining vasodilation in humans.","journal-title":"Hypertension"},{"key":"95_CR34","first-page":"R1071","volume":"276","author":"T Ohuchi","year":"1999","unstructured":"Ohuchi T, Kuwaki T, Ling GY, et al.: Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol 1999, 276:R1071-R1077. Important study demonstrating a causative role for the ETB receptor in normotension.","journal-title":"Am J Physiol"},{"key":"95_CR35","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1172\/JCI8609","volume":"105","author":"CE Gariepy","year":"2000","unstructured":"Gariepy CE, Ohuchi T, Williams SC, et al.: Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 2000, 105:925\u2013933.","journal-title":"J Clin Invest"},{"key":"95_CR36","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/01.CIR.102.22.2765","volume":"102","author":"Y Matsumura","year":"2000","unstructured":"Matsumura Y, Kuro T, Kobayashi Y, et al.: Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation 2000, 102:2765\u20132773. This study demonstrated sensitivity to treatment with ETA antagonists in ETB-deficient salt-sensitive hypertensive rats.","journal-title":"Circulation"},{"key":"95_CR37","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","volume":"338","author":"H Krum","year":"1998","unstructured":"Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998, 338:784\u2013790. This study demonstrated therapeutic potential of ET antagonists in patients with essential hypertension.","journal-title":"N Engl J Med"},{"key":"95_CR38","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1161\/01.HYP.35.1.329","volume":"35","author":"M Barton","year":"2000","unstructured":"Barton M, Carmona R, Morawietz H, et al.: Obesity is associated with tissue-specific activation of renal angiotensin converting enzyme in vivo. Evidence for a regulatory role of endothelin. Hypertension 2000, 35[part 2]:329\u2013336.","journal-title":"Hypertension"},{"key":"95_CR39","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1161\/01.HYP.33.5.1169","volume":"33","author":"L Tiret","year":"1999","unstructured":"Tiret L, Poirier O, Hallet V, et al.: The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999, 33:1169\u20131174.","journal-title":"Hypertension"},{"key":"95_CR40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.HYP.23.3.381","volume":"23","author":"JE Hall","year":"1994","unstructured":"Hall JE, Louis K: Dahl Memorial Lecture. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension 1994, 23:381\u2013394.","journal-title":"Hypertension"},{"key":"95_CR41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/01.CIR.90.1.27","volume":"90","author":"W Kiowski","year":"1994","unstructured":"Kiowski W, Linder L, Stoschitzky K, et al.: Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 1994, 90:27\u201334.","journal-title":"Circulation"},{"key":"95_CR42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1172\/JCI116604","volume":"92","author":"S Kourembanas","year":"1993","unstructured":"Kourembanas S, McQuillan LP, et al.: Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993, 92:99\u2013104.","journal-title":"J Clin Invest"},{"key":"95_CR43","first-page":"1125","volume-title":"Heart Disease","author":"AM Gotto","year":"1992","unstructured":"Gotto AM, Farmer JA.: Risk factors for coronary artery disease. In Heart Disease, edn 2. Edited by Braunwald E. Philadelphia: WB Saunders; 1992:1125\u20131160.","edition":"edn 2"},{"key":"95_CR44","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.HYP.30.4.817","volume":"30","author":"M Barton","year":"1997","unstructured":"Barton M, Cosentino F, Brandes RP, et al.: Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension 1997, 30:817\u2013824.","journal-title":"Hypertension"},{"key":"95_CR45","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1006\/bbrc.2000.4180","volume":"280","author":"W Goettsch","year":"2001","unstructured":"Goettsch W, Lattmann T, Amann K, et al.: Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: Implications for atherosclerosis. Biochem Biophys Res Commun 2001, 280:908\u2013913.","journal-title":"Biochem Biophys Res Commun"},{"key":"95_CR46","first-page":"619","volume":"34","author":"M Barton","year":"1999","unstructured":"Barton M, Lattmann T, Shaw S, et al.: Marked increase of endothelin-1 and endothelin-3 protein with aging in the rat kidney in vivo independent of blood pressure, estrogen, and endothelin-1 clearance. Hypertension 1999, 34:619.","journal-title":"Hypertension"},{"key":"95_CR47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1172\/JCI114688","volume":"86","author":"MA Creager","year":"1990","unstructured":"Creager MA, Cooke JP, Mendelsohn ME, et al.: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 1990, 86:228\u2013234.","journal-title":"J Clin Invest"},{"key":"95_CR48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/BF00252823","volume":"72","author":"W Gross","year":"1994","unstructured":"Gross W, Usadel KH: Elevated endothelin levels in patients with hyperlipoproteinemia. Clin Invest 1994, 72:580\u2013584.","journal-title":"Clin Invest"},{"key":"95_CR49","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/01.CIR.92.9.2426","volume":"92","author":"A Lerman","year":"1995","unstructured":"Lerman A, Holmes DJ, Bell MR, et al.: Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995, 92:2426\u20132431.","journal-title":"Circulation"},{"key":"95_CR50","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1161\/01.CIR.96.6.1930","volume":"96","author":"V Mathew","year":"1997","unstructured":"Mathew V, Cannan CR, Miller VM, et al.: Enhanced endothelinmediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation 1997, 96:1930\u20131936.","journal-title":"Circulation"},{"key":"95_CR51","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/01.CIR.99.13.1747","volume":"99","author":"PJ Best","year":"1999","unstructured":"Best PJ, McKenna CJ, Hasdai D, et al.: Chronic endothelin receptor antagonism preserves coronary endothelial function in experimental hypercholesterolemia. Circulation 1999, 99:1747\u20131752.","journal-title":"Circulation"},{"key":"95_CR52","first-page":"819","volume":"146","author":"MC Kowala","year":"1995","unstructured":"Kowala MC, Rose PM, Stein PD, et al.: Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995, 146:819\u2013286.","journal-title":"Am J Pathol"},{"key":"95_CR53","doi-asserted-by":"crossref","first-page":"14367","DOI":"10.1073\/pnas.95.24.14367","volume":"95","author":"M Barton","year":"1998","unstructured":"Barton M, Haudenschild CC, d\u2019Uscio LV, et al.: Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apoE-deficient mice. Proc Natl Acad Sci U S A 1998, 95:14367\u201314372.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"95_CR54","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1161\/01.ATV.19.11.2769","volume":"19","author":"PJ Best","year":"1999","unstructured":"Best PJ, Lerman LO, Romero JC, et al.: Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia In vitro. Arterioscler Thromb Vasc Biol 1999, 19:2769\u20132775.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"95_CR55","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1152\/jappl.2001.90.3.816","volume":"90","author":"CB Taner","year":"2001","unstructured":"Taner CB, Severson SR, Best PJ, et al.: Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia. J Appl Physiol 2001, 90:816\u2013820. Interesting observation of increased NO synthase activity independent of NO synthase expression after chronic ET blockade, providing a possible mechanism for the increase in plasma metabolites observed in earlier studies.","journal-title":"J Appl Physiol"},{"key":"95_CR56","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1006\/bbrc.2000.2354","volume":"269","author":"N Duerrschmidt","year":"2000","unstructured":"Duerrschmidt N, Wippich N, Goettsch W, et al.: Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 2000, 269:713\u2013717. The first paper showing direct stimulatory effects of ET-1 on NADPH oxidase expression and activity.","journal-title":"Biochem Biophys Res Commun"},{"key":"95_CR57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0008-6363(00)00083-3","volume":"47","author":"J Bauersachs","year":"2000","unstructured":"Bauersachs J, Fraccarollo D, Galuppo P, et al.: Endothelinreceptor blockade improves endothelial vasomotor dysfunction in heart failure. Cardiovasc Res 2000, 47:142\u2013149. Interesting report demonstrating a role for ET-1 in abnormal endothelium-dependent vasomotion in heart failure.","journal-title":"Cardiovasc Res"},{"key":"95_CR58","doi-asserted-by":"crossref","first-page":"H1105","DOI":"10.1152\/ajpheart.2001.280.3.H1105","volume":"280","author":"AV Gourine","year":"2001","unstructured":"Gourine AV, Gonon AT, Pernow J: Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2001, 280:H1105-H1112.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"95_CR59","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM199110033251404","volume":"325","author":"A Lerman","year":"1991","unstructured":"Lerman A, Edwards BS, Hallett JW, et al.: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991, 325:997\u20131001.","journal-title":"N Engl J Med"},{"key":"95_CR60","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.95.1.221","volume":"95","author":"T Minamino","year":"1997","unstructured":"Minamino T, Kurihara H, Takahashi M, et al.: Endothelinconverting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation 1997, 95:221\u2013230.","journal-title":"Circulation"},{"key":"95_CR61","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/01.CIR.99.9.1147","volume":"99","author":"GP Rossi","year":"1999","unstructured":"Rossi GP, Colonna S, Pavan E, et al.: Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation 1999, 99:1147\u20131155. Very comprehensive study investigating components of the ET system in normal and atherosclerotic human arteries.","journal-title":"Circulation"},{"key":"95_CR62","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/01.CIR.91.4.941","volume":"91","author":"AM Zeiher","year":"1995","unstructured":"Zeiher AM, Goebel H, Schachinger V, Ihling C: Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995, 91:941\u2013947.","journal-title":"Circulation"},{"key":"95_CR63","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1006\/bbrc.1993.1327","volume":"191","author":"JA Winkles","year":"1993","unstructured":"Winkles JA, Alberts GF, Brogi E, Libby P: Endothelin-1 and endothelin receptor mRNA expression in normal and atherosclerotic human arteries. Biochem Biophys Res Commun 1993, 191:1081\u20131088.","journal-title":"Biochem Biophys Res Commun"},{"key":"95_CR64","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0021-9150(99)00134-3","volume":"146","author":"S Iwasa","year":"1999","unstructured":"Iwasa S, Fan J, Shimokama T, et al.: Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis. Atherosclerosis 1999, 146:93\u2013100.","journal-title":"Atherosclerosis"},{"key":"95_CR65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11906-000-0064-5","volume":"2","author":"M Barton","year":"2000","unstructured":"Barton M: Endothelial dysfunction and atherosclerosis: endothelin receptor antagonists as novel therapeutics. Curr Hypertens Rep 2000, 2:84\u201391.","journal-title":"Curr Hypertens Rep"},{"key":"95_CR66","first-page":"I","volume":"100","author":"S Iwasa","year":"1999","unstructured":"Iwasa S, Fan J, Miyauchi T, Watanabe T: Non-selective endothelin receptor antagonist, SB209670, reduces diet-induced hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice. Circulation 1999, 100(suppl):I-474.","journal-title":"Circulation"},{"key":"95_CR67","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0008-6363(00)00169-3","volume":"48","author":"S Babaei","year":"2000","unstructured":"Babaei S, Picard P, Ravandi A, et al.: Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. Cardiovasc Res 2000, 48:158\u2013167. Interesting paper suggesting a role for ET-1 in foam cell formation.","journal-title":"Cardiovasc Res"},{"key":"95_CR68","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1161\/01.RES.78.2.322","volume":"78","author":"X Wang","year":"1996","unstructured":"Wang X, Douglas SA, Louden C, et al.: Expression of endothelin-1, endothelin-3, endothelin-converting enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res 1996, 78:322\u2013328.","journal-title":"Circ Res"},{"key":"95_CR69","doi-asserted-by":"crossref","first-page":"S371","DOI":"10.1097\/00005344-199322008-00097","volume":"22","author":"SA Douglas","year":"1993","unstructured":"Douglas SA, Ohlstein EH: Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. J Cardiovasc Pharmacol 1993, 22:S371\u2013373.","journal-title":"J Cardiovasc Pharmacol"},{"key":"95_CR70","doi-asserted-by":"crossref","first-page":"L449","DOI":"10.1016\/0024-3205(95)00219-V","volume":"56","author":"M Tsujino","year":"1995","unstructured":"Tsujino M, Hirata Y, Eguchi S, et al.: Nonselective ETA\/ETB receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. Life Sci 1995, 56:L449\u2013454.","journal-title":"Life Sci"},{"key":"95_CR71","first-page":"90","volume":"6","author":"K M\u00fcnter","year":"1996","unstructured":"M\u00fcnter K, Hergenr\u00f6der S, Unger L, Kirchengast M: A-receptor antagonist inhibits neointima formation induced by endothelial injury. Oral treatment with and ET. Pharm Pharmacol Lett 1996, 6:90\u201392.","journal-title":"Pharm Pharmacol Lett"},{"key":"95_CR72","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1164\/ajrccm.157.6.9709131","volume":"157","author":"H Shennib","year":"1998","unstructured":"Shennib H, Lee AG, Kuang JQ, et al.: Efficacy of administering an endothelin-receptor antagonist (SB209670) in ameliorating ischemia-reperfusion injury in lung allografts. Am J Respir Crit Care Med 1998, 157:1975\u20131981.","journal-title":"Am J Respir Crit Care Med"},{"key":"95_CR73","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1161\/01.CIR.97.23.2346","volume":"97","author":"K Okada","year":"1998","unstructured":"Okada K, Nishida Y, Murakami H, et al.: Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts: antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation 1998, 97:2346\u20132351.","journal-title":"Circulation"},{"key":"95_CR74","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1681\/ASN.V102387","volume":"10","author":"SR Orth","year":"1999","unstructured":"Orth SR, Odoni G, Amann K, et al.: The ETA receptor blocker LU 135252 prevents chronic transplant nephropathy in the \u201cFisher to Lewis\u201d model. J Am Soc Nephrol 1999, 10:387\u2013391. Highly interesting study suggesting that ET receptor blockade may inhibit transplant-associated renal injury and vascular disease independent of immunosuppression.","journal-title":"J Am Soc Nephrol"},{"key":"95_CR75","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/01.CIR.98.16.1684","volume":"98","author":"J Dupuis","year":"1998","unstructured":"Dupuis J, Rouleau JL, Cernacek P: Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. Circulation 1998, 98:1684\u20131687.","journal-title":"Circulation"},{"key":"95_CR76","doi-asserted-by":"crossref","first-page":"L690","DOI":"10.1152\/ajpcell.1995.269.3.C690","volume":"269","author":"VS DiCarlo","year":"1995","unstructured":"DiCarlo VS, Chen SJ, Meng QC, et al.: ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol 1995, 269:L690-L697.","journal-title":"Am J Physiol"},{"key":"95_CR77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1161\/01.CIR.97.21.2169","volume":"97","author":"S Prie","year":"1998","unstructured":"Prie S, Stewart DJ, Dupuis J: EndothelinA receptor blockade improves nitric oxide-mediated vasodilation in monocrotalineinduced pulmonary hypertension. Circulation 1998, 97:169\u2013174.","journal-title":"Circulation"},{"key":"95_CR78","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/pupt.1999.0158","volume":"12","author":"DC Underwood","year":"1999","unstructured":"Underwood DC, Bochonowicz S, Osborn RR, et al.: Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high-altitude-sensitive rat. Pulm Pharmacol Ther 1999, 12:13\u201326.","journal-title":"Pulm Pharmacol Ther"},{"key":"95_CR79","volume-title":"Heart Disease. A Textbook of Cardiovascular Medicine.","author":"E Braunwald","year":"1992","unstructured":"Braunwald E: Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders; 1992."},{"key":"95_CR80","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1161\/01.CIR.82.6.2226","volume":"82","author":"KB Margulies","year":"1990","unstructured":"Margulies KB, Hildebrand FJ, Lerman A, et al.: Increased endothelin in experimental heart failure. Circulation 1990, 82:2226\u20132230.","journal-title":"Circulation"},{"key":"95_CR81","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0002-9149(97)00096-9","volume":"79","author":"E Mangieri","year":"1997","unstructured":"Mangieri E, Tanzilli G, Barilla F, et al.: Isometric handgrip exercise increases endothelin-1 plasma levels in patients with chronic congestive heart failure. Am J Cardiol 1997, 79:1261\u20131263.","journal-title":"Am J Cardiol"},{"key":"95_CR82","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/01.CIR.89.4.1573","volume":"89","author":"T Omland","year":"1994","unstructured":"Omland T, Lie RT, Aakvaag A, et al.: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994, 89:1573\u20131579.","journal-title":"Circulation"},{"key":"95_CR83","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/384353a0","volume":"384","author":"S Sakai","year":"1996","unstructured":"Sakai S, Miyauchi T, Kobayashi M, et al.: Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996, 384:353\u2013355.","journal-title":"Nature"},{"key":"95_CR84","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1097\/00005344-199800001-00120","volume":"31","author":"M Fukuchi","year":"1998","unstructured":"Fukuchi M, Giaid A: Expression of endothelin-1 and endothelinconverting-enyzme-1 mRNAs and proteins in failing human hearts. J Cardiovasc Pharmacol 1998, 31:S421-S423.","journal-title":"J Cardiovasc Pharmacol"},{"key":"95_CR85","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1161\/01.CIR.97.8.744","volume":"97","author":"K P\u00f6nicke","year":"1998","unstructured":"P\u00f6nicke K, Vogelsang M, Heinroth M, et al.: Endothelin receptors in the failing and nonfailing human heart. Circulation 1998, 97:744\u2013751.","journal-title":"Circulation"},{"key":"95_CR86","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1161\/01.CIR.99.16.2171","volume":"99","author":"R Yamauchi-Kohno","year":"1999","unstructured":"Yamauchi-Kohno R, Miyauchi T, Kobayashi T, et al.: Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters. Increase in endothelin1-production in the heart and beneficial effects of endothelin-A receptor antagonist on survival and cardiac function. Circulation 1999, 99:2171\u20132176. This study suggests the therapeutic potential of ET receptor antagonists in cardiomyopathy.","journal-title":"Circulation"},{"key":"95_CR87","doi-asserted-by":"crossref","first-page":"III188","DOI":"10.1161\/01.CIR.102.suppl_3.III-188","volume":"102","author":"H Morawietz","year":"2000","unstructured":"Morawietz H, Szibor M, Goettsch W, et al.: Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ET(A) receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure. Circulation 2000, 102:III188-III193. This study demonstrated normalization of increased ETA receptor expression after ventricular deloading in patients with severe heart failure, suggesting that filling pressures may regulate myocardial ET receptor expression.","journal-title":"Circulation"},{"key":"95_CR88","first-page":"H2105","volume":"275","author":"S Maeda","year":"1998","unstructured":"Maeda S, Miyauchi T, Sakai S, et al.: Prolonged exercise causes an increase in endothelin-1 production in the heart in rats. Am J Physiol 1998, 275:H2105-H2112.","journal-title":"Am J Physiol"},{"key":"95_CR89","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.CIR.93.6.1214","volume":"93","author":"S Sakai","year":"1996","unstructured":"Sakai S, Miyauchi T, Sakurai T, et al.: Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 1996, 93:1214\u20131222.","journal-title":"Circulation"},{"key":"95_CR90","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1172\/JCI116579","volume":"92","author":"H Ito","year":"1993","unstructured":"Ito H, Hirata Y, Adachi S, et al.: Endothelin-1 is an autocrine\/ paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993, 92:398\u2013403.","journal-title":"J Clin Invest"},{"key":"95_CR91","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1006\/jmcc.1996.0117","volume":"28","author":"H Ito","year":"1996","unstructured":"Ito H, Adachi S, Tamamori M, et al.: Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism. J Mol Cell Cardiol 1996, 28:1271\u20131277.","journal-title":"J Mol Cell Cardiol"},{"key":"95_CR92","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0008-6363(98)00121-7","volume":"40","author":"MO Gray","year":"1998","unstructured":"Gray MO, Long CS, Kalinyak JE, et al.: Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts. Cardiovasc Res 1998, 40:352\u2013363.","journal-title":"Cardiovasc Res"},{"key":"95_CR93","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1161\/01.CIR.99.16.2118","volume":"99","author":"O Zolk","year":"1999","unstructured":"Zolk O, Quattek J, Sitzler G, et al.: Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 1999, 99:2118\u20132123.","journal-title":"Circulation"},{"key":"95_CR94","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(05)77807-7","volume":"352","author":"PJ Cowburn","year":"1998","unstructured":"Cowburn PJ, Cleland JGF, McArthur JD, et al.: Short-term haemodynamic effect of BQ-123, a selective endothelinAreceptor antagonist, in chronic heart failure. Lancet 1998, 352:201\u2013202.","journal-title":"Lancet"},{"key":"95_CR95","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0735-1097(00)00649-5","volume":"35","author":"LE Spieker","year":"2000","unstructured":"Spieker LE, Mitrovic V, Noll G, et al.: Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 2000, 35:1745\u20131752.","journal-title":"J Am Coll Cardiol"},{"key":"95_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.CIR.98.1.1","volume":"98","author":"M Packer","year":"1998","unstructured":"Packer M, Caspi A, Charlon V, et al.: Multicenter, double-blind, placebo-controlled study of long-term endothelin blockade with bosentan in chronic heart failure. Results of the REACH-1 trial. Circulation 1998, 98:1\u20133.","journal-title":"Circulation"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-001-0095-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0095-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T07:16:26Z","timestamp":1628925386000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-001-0095-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1007\/s11906-001-0095-6","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}